IP Verse

Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof

Patent No. EP3692983 (titled "Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof") was filed by Celgene on May 14, 2009. The application was issued on Aug 11, 2021.

Patent Summary

Oral formulations of cytidine analogs like 5-azacytidine for treating diseases like cancer that avoid the need for enteric coating to protect the drugs from stomach acid. The compositions are immediate release tablets or capsules that release the drug substantially in the stomach following oral administration. This enables higher doses, improved pharmacokinetics, and convenience compared to enteric-coated formulations. The compositions may contain excipients and permeation enhancers but avoid cytidine deaminase inhibitors.

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKMay 11, 2022ELKINGTON AND FIFE
STADA ARZNEIMITTELMay 11, 2022KERNEBECK
HOFFMANN EITLEMay 10, 2022HOFFMANN EITLE
TEVA PHARMACEUTICALSMay 10, 2022D YOUNG
SANDOZMay 9, 2022TER MEER STEINMEISTER & PARTNER
LOTUS PHARMACEUTICALApr 29, 2022HAMM & WITTKOPP

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3692983

CELGENE
Application Number
EP19213148A
Filing Date
May 14, 2009
Status
Opposition Rejected
Sep 6, 2025
Publication Date
Aug 11, 2021
External Links
Slate, Register , Google Patents